Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 7/20 | 0.38 |
| ▸ | HTR1B | P28222 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22126572 | 0.82 | CYP2A6 (0.50) | CYP2A6IMPDH2P2RX7HTR1DHTR1B | |
| SCHEMBL29955620 | 0.82 | CYP2A6 (0.50) | CYP2A6IMPDH2P2RX7HTR1DHTR1B | |
| SCHEMBL16727129 | 0.79 | CYP2A6 (0.47) | CYP2A6IMPDH2P2RX7HTR1DHTR1B | |
| SCHEMBL29954945 | 0.79 | CYP2A6 (0.47) | CYP2A6IMPDH2P2RX7HTR1DHTR1B | |
| SCHEMBL29953119 | 0.79 | CYP2A6 (0.47) | CYP2A6IMPDH2P2RX7HTR1DHTR1B | |
| SCHEMBL26653873 | 0.79 | CYP2A6 (0.56) | CYP2A6IMPDH2P2RX7HTR1DHTR1B | |
| SCHEMBL6859382 | 0.76 | ALDH1A1 (0.48) | CYP2A6IMPDH2HTR1DHTR1BALDH1A1 | |
| SCHEMBL29951455 | 0.76 | ALDH1A1 (0.48) | CYP2A6IMPDH2P2RX7HTR1DHTR1B | |
| SCHEMBL29951940 | 0.75 | CYP2A6 (0.64) | CYP2A6IMPDH2P2RX7HTR1DHTR1B | |
| SCHEMBL1337252 | 0.75 | CYP2A6 (0.64) | CYP2A6IMPDH2P2RX7HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831075-B2 | Administering to a host for inhibiting kinase activity a 5-heterocylcic subustituted pyrazolone derivative | CEPHALON, INC. | 2004-12-14 | — | — | US | disclosed |
| US-20030162775-A1 | Heterocyclic substituted pyrazolones | CEPHALON, INC. | 2003-08-28 | — | — | US | disclosed |
| CN-1387528-A | Heterocyclic substd, pyrazolones | CEPHALON INC (US) | 2002-12-25 | — | — | CN | disclosed |
| US-6455525-B1 | Heterocyclic substituted pyrazolones | CEPHALON, INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1226141-A1 | HETEROCYCLIC SUBSTITUTED PYRAZOLONES | CEPHALON, INC. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001032653-A1 | HETEROCYCLIC SUBSTITUTED PYRAZOLONES | CEPHALON, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162775-A1 | Heterocyclic substituted pyrazolones | CYP3A4, CYP3A5, PDXK | CYP2A6 226/4885IMPDH2 425/4885P2RX7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.